Added to YB: 2026-03-09
Pitch date: 2025-12-24
BDX [bullish]
Becton, Dickinson and Company
+4.26%
current return
Author Info
No bio for this author
Company Info
Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide.
Market Cap
$47.6B
Pitch Price
$153.11
Price Target
N/A
Dividend
2.51%
EV/EBITDA
10.64
P/E
27.29
EV/Sales
3.03
Sector
Health Care Equipment and Supplies
Category
special_situation
Becton, Dickinson and Company - $BDX
BDX: MedTech at 13.5x P/E despite defensive biz w/ 25% OI margin, 51.9% gross margin. Market discounts Alaris/China/vaccine/tariff headwinds hitting FY26. Q1 2026 spin of Biosciences+Diagnostics to WAT delivers $14.8B equity (39.2% stake) + $4B cash = $65.5/share value. RemainCo $37.5B mcap at 6% FCF yield vs peers 3-4%. Base case 5yr: 5% rev growth, 8% OI growth, 10-15% total return. 3yr IRR: low-teens base, principal protected downside, 20%+ upside on re-rating. Catalysts: spin close, 2026 Capital Day, headwind resolution.
Read full article (5 min)